Pharma
Alivus Life Sciences Ltd
ALIVUS · NSE · INE03Q201024Tuesday, 27 Oct 2026Vol: 44.5K traded · 55.4% delivered9:31 am
Market Cap₹15,691 Cr
P/E26.1
P/B4.7
EPS₹49.03
Div Yield0.4%
ROE18.4%
ROCE21.6%
ROE18.4%
1Y Return+56.09%
Avg. Volume0.2M
Delivery %55.35%
Price Chart
52-Week Range
About
Alivus Life Sciences Ltd is a Pharma company listed on NSE.
Technicals
Free account
Register freeTechnicals
Create a free account to view momentum, moving averages, and delivery signals.
Quant
Premium
UpgradeQuant metrics
Upgrade to view volatility, drawdown, factor, and risk metrics.
Key Ratios
Market Cap₹15,691 Cr
Current Price₹1,278.1
52W High / Low₹1,493.8 / ₹819
Stock P/E26.1
Price to Book4.7
EPS (TTM)₹49.03
Dividend Yield0.4%
ROE18.4%
1Y Return+56.09%
Day Change+1.28%
Profit & Loss
| Period | FY26 | FY25 | FY24 | FY23 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Sales | ₹2,504 Cr | ₹2,340 Cr | ₹2,185 Cr | ||||
| Expenses | ₹1,782 Cr | ₹1,716 Cr | ₹1,563 Cr | ||||
| Operating Profit | ₹722 Cr | ₹624 Cr | ₹622 Cr | ||||
| OPM % | 28.9% | 26.7% | 28.5% | ||||
| Other Income | ₹1 Cr | ₹3 Cr | ₹0 Cr | ||||
| Depreciation | ₹75 Cr | ₹61 Cr | ₹53 Cr | ||||
| Interest | ₹5 Cr | ₹2 Cr | ₹2 Cr | ||||
| Profit Before Tax | ₹751 Cr | ₹654 Cr | ₹631 Cr | ||||
| Tax | ₹187 Cr | ₹169 Cr | ₹160 Cr | ||||
| Net Profit | ₹564 Cr | ₹486 Cr | ₹471 Cr | ||||
| EPS (₹) | 45.9 | 39.5 | 38.4 | ||||
| Dividend Payout % | — | — | — |
Financial history locked
Register freeRegister free to see 4 more years.
Quarterly Results
| Quarter | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Sales | ₹640 Cr | ₹689 Cr | ₹673 Cr | ₹602 Cr | |
| Expenses | ₹449 Cr | ₹495 Cr | ₹461 Cr | ₹447 Cr | |
| Operating Profit | ₹191 Cr | ₹194 Cr | ₹212 Cr | ₹155 Cr | |
| OPM % | 29.8% | 28.2% | 31.5% | 25.8% | |
| Depreciation | — | — | — | — | |
| Interest | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | |
| Net Profit | ₹160 Cr | ₹163 Cr | ₹150 Cr | ₹122 Cr | |
| EPS (₹) | 13.0 | 13.2 | 12.2 | 9.9 |
Quarterly history locked
Register freeRegister free to see 1 more quarter.
Balance Sheet
| Period | FY26 | FY25 | FY24 | FY23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹25 Cr | ₹25 Cr | ₹25 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹3,308 Cr | ₹2,793 Cr | ₹2,308 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹57 Cr | ₹57 Cr | ₹17 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹594 Cr | ₹537 Cr | ₹501 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹3,983 Cr | ₹3,411 Cr | ₹2,850 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹1,297 Cr | ₹1,046 Cr | ₹905 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹780 Cr | ₹478 Cr | ₹91 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | ₹1,073 Cr | ₹970 Cr | ₹765 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | ₹692 Cr | ₹674 Cr | ₹667 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | ₹2 Cr | ₹71 Cr | ₹301 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹139 Cr | ₹173 Cr | ₹122 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹3,983 Cr | ₹3,411 Cr | ₹2,850 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance sheet history locked
Register freeRegister free to see 4 more years.
Cash Flow
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| FY26 | ₹565 Cr | ₹-570 Cr | ₹-64 Cr | ₹-69 Cr |
| FY25 | ₹392 Cr | ₹-616 Cr | ₹-6 Cr | ₹-230 Cr |
| FY24 | ₹414 Cr | ₹-116 Cr | ₹-279 Cr | ₹18 Cr |
| FY23 |
Cash flow history locked
Register freeRegister free to see 4 more years.
Peer Comparison
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| 3B BlackBio Dx Ltd | ₹1,210 Cr | 21.4 | +20.2% | +17.9% |
| Aarey Drugs & Pharmaceuticals Ltd | — | — | +2.75% | +59.84% |
| Aarti Drugs Ltd | ₹3,429 Cr | 18.0 | +13.37% | +11.57% |
| Aarti Pharmalabs Ltd | ₹7,495 Cr | 35.2 | +8.51% | +14.26% |
| Abbott India Ltd | — | — | +34.46% | -7.16% |
Mutual Fund Holdings
Free account
Register freeMutual fund holdings
Create a free account to see institutional ownership snapshots.
Bulk & Block Deals
Free account
Register freeBulk & block deals
Create a free account to view recent institutional deal activity.
Analyst Estimates
Free account
Register freeAnalyst estimates
Create a free account to view analyst estimate summaries.
Latest News
2026-09-16The Company Has Incorporated A Wholly Owned Subsidiary Company In Brazil.BSE Filing2026-07-31Alivus Life Sciences Ltd (BOM:543322) (Q1 2027) Earnings Call Highlights: Margin Surge and ...GuruFocus.com2026-07-30Alivus Life Sciences Ltd (BOM:543322) Q1 2027 Earnings Report Preview: What To Look ForGuruFocus.com
Documents & Filings
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.